(Q24241157)

ChEBI release 2020-05-28

1 reference

8

0 references

Andrea Cipriani

1

0 references

Rachel Churchill

6

0 references

Hugh McGuire

7

Hugh McGuire

0 references

Toshi A Furukawa

3

Toshi A Furukawa

0 references

Teresa La Ferla

2

Teresa La Ferla

0 references

Alessandra Signoretti

4

Alessandra Signoretti

0 references

Atsuo Nakagawa

5

Cochrane Database of Systematic Reviews

Atsuo Nakagawa

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

Australian and New Zealand clinical practice guidelines for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

Clinician's judgments of mental health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Placebo in clinical trials for depression: complexity and necessity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Sertraline treatment of major depression in patients with acute MI or unstable angina

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Fluoxetine versus other types of pharmacotherapy for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Fluvoxamine versus other anti-depressive agents for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Mirtazapine versus other anti-depressive agents for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Milnacipran versus other anti-depressive agents for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Duloxetine versus other anti-depressive agents for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Citalopram versus other anti-depressive agents for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Network meta-analysis for indirect treatment comparisons

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Are we going to increase the use of antidepressants up to that of benzodiazepines?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Imputing missing standard deviations in meta-analyses can provide accurate results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Why are so few randomized trials useful, and what can we do about it?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Awareness, diagnosis, and treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Expanding the black box - depression, antidepressants, and the risk of suicide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Imputing response rates from means and standard deviations in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A national survey of cardiovascular physicians' beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Treatment of anxiety and depressive disorders in patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Venlafaxine for major depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Evaluation of networks of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Clinical trials of antidepressant medications are producing meaningless results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Industry sponsorship and authorship of clinical trials over 20 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021

A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006117.PUB2

7 January 2021